The Golgi Apparatus as an Anticancer Therapeutic Target

Although the discovery of the Golgi apparatus (GA) was made over 125 years ago, only a very limited number of therapeutic approaches have been developed to target this complex organelle. The GA serves as a modification and transport center for proteins and lipids and also has more recently emerged a...

Full description

Bibliographic Details
Published in:Biology
Main Authors: Marta Martins, João Vieira, Catarina Pereira-Leite, Nuno Saraiva, Ana Sofia Fernandes
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Subjects:
Online Access:https://www.mdpi.com/2079-7737/13/1/1
_version_ 1850146643510296576
author Marta Martins
João Vieira
Catarina Pereira-Leite
Nuno Saraiva
Ana Sofia Fernandes
author_facet Marta Martins
João Vieira
Catarina Pereira-Leite
Nuno Saraiva
Ana Sofia Fernandes
author_sort Marta Martins
collection DOAJ
container_title Biology
description Although the discovery of the Golgi apparatus (GA) was made over 125 years ago, only a very limited number of therapeutic approaches have been developed to target this complex organelle. The GA serves as a modification and transport center for proteins and lipids and also has more recently emerged as an important store for some ions. The dysregulation of GA functions is implicated in many cellular processes associated with cancer and some GA proteins are indeed described as cancer biomarkers. This dysregulation can affect protein modification, localization, and secretion, but also cellular metabolism, redox status, extracellular pH, and the extracellular matrix structure. Consequently, it can directly or indirectly affect cancer progression. For these reasons, the GA is an appealing anticancer pharmacological target. Despite this, no anticancer drug specifically targeting the GA has reached the clinic and few have entered the clinical trial stage. Advances in nanodelivery approaches may help change this scenario by specifically targeting tumor cells and/or the GA through passive, active, or physical strategies. This article aims to examine the currently available anticancer GA-targeted drugs and the nanodelivery strategies explored for their administration. The potential benefits and challenges of modulating and specifically targeting the GA function in the context of cancer therapy are discussed.
format Article
id doaj-art-77402a24c8024c3ca40cbfd4f6838bdf
institution Directory of Open Access Journals
issn 2079-7737
language English
publishDate 2023-12-01
publisher MDPI AG
record_format Article
spelling doaj-art-77402a24c8024c3ca40cbfd4f6838bdf2025-08-19T23:47:08ZengMDPI AGBiology2079-77372023-12-01131110.3390/biology13010001The Golgi Apparatus as an Anticancer Therapeutic TargetMarta Martins0João Vieira1Catarina Pereira-Leite2Nuno Saraiva3Ana Sofia Fernandes4CBIOS—Universidade Lusófona’s Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024 Lisboa, PortugalCBIOS—Universidade Lusófona’s Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024 Lisboa, PortugalCBIOS—Universidade Lusófona’s Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024 Lisboa, PortugalCBIOS—Universidade Lusófona’s Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024 Lisboa, PortugalCBIOS—Universidade Lusófona’s Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024 Lisboa, PortugalAlthough the discovery of the Golgi apparatus (GA) was made over 125 years ago, only a very limited number of therapeutic approaches have been developed to target this complex organelle. The GA serves as a modification and transport center for proteins and lipids and also has more recently emerged as an important store for some ions. The dysregulation of GA functions is implicated in many cellular processes associated with cancer and some GA proteins are indeed described as cancer biomarkers. This dysregulation can affect protein modification, localization, and secretion, but also cellular metabolism, redox status, extracellular pH, and the extracellular matrix structure. Consequently, it can directly or indirectly affect cancer progression. For these reasons, the GA is an appealing anticancer pharmacological target. Despite this, no anticancer drug specifically targeting the GA has reached the clinic and few have entered the clinical trial stage. Advances in nanodelivery approaches may help change this scenario by specifically targeting tumor cells and/or the GA through passive, active, or physical strategies. This article aims to examine the currently available anticancer GA-targeted drugs and the nanodelivery strategies explored for their administration. The potential benefits and challenges of modulating and specifically targeting the GA function in the context of cancer therapy are discussed.https://www.mdpi.com/2079-7737/13/1/1cancerGolgi apparatustherapynanotechnologysubcellular targeting
spellingShingle Marta Martins
João Vieira
Catarina Pereira-Leite
Nuno Saraiva
Ana Sofia Fernandes
The Golgi Apparatus as an Anticancer Therapeutic Target
cancer
Golgi apparatus
therapy
nanotechnology
subcellular targeting
title The Golgi Apparatus as an Anticancer Therapeutic Target
title_full The Golgi Apparatus as an Anticancer Therapeutic Target
title_fullStr The Golgi Apparatus as an Anticancer Therapeutic Target
title_full_unstemmed The Golgi Apparatus as an Anticancer Therapeutic Target
title_short The Golgi Apparatus as an Anticancer Therapeutic Target
title_sort golgi apparatus as an anticancer therapeutic target
topic cancer
Golgi apparatus
therapy
nanotechnology
subcellular targeting
url https://www.mdpi.com/2079-7737/13/1/1
work_keys_str_mv AT martamartins thegolgiapparatusasananticancertherapeutictarget
AT joaovieira thegolgiapparatusasananticancertherapeutictarget
AT catarinapereiraleite thegolgiapparatusasananticancertherapeutictarget
AT nunosaraiva thegolgiapparatusasananticancertherapeutictarget
AT anasofiafernandes thegolgiapparatusasananticancertherapeutictarget
AT martamartins golgiapparatusasananticancertherapeutictarget
AT joaovieira golgiapparatusasananticancertherapeutictarget
AT catarinapereiraleite golgiapparatusasananticancertherapeutictarget
AT nunosaraiva golgiapparatusasananticancertherapeutictarget
AT anasofiafernandes golgiapparatusasananticancertherapeutictarget